Collegium Caps 2025 with Portfolio Pivot; CRAI Signals High Pharma Demand
Collegium Pharmaceutical's Q4 2025 results showcase a successful strategic shift toward diversification, led by the ADHD treatment Jornay PM. Simultaneously, CRA International’s earnings highlight a surging demand for specialized life sciences consulting amid a complex regulatory landscape.